Core C: Biospecimen and Pathology Core

核心 C：生物样本和病理学核心

基本信息

批准号：
10468828
负责人：
STEVEN R ALBERTS
金额：
$ 27.81万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-10 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10468828
关键词：
Address Aliquot Animal Model Arizona Bacterial Artificial Chromosomes Basic Science Biliary Bioinformatics Biological Specimen Banks Biometry Biopsy Blood Blood Platelets Blood specimen Cancer Model Cancer Patient Cell Line Cessation of life Characteristics Cholangiocarcinoma Cholestasis Clinic Clinical Clinical Data Clinical Research Consent Core Facility DNA Data Databases Development Diagnosis Diagnostic Dietary History Disease Early Diagnosis Evaluation Excision Family Fibrolamellar Hepatocellular Carcinoma Florida Formalin Freezing Frozen Sections Funding Future Genes Genetic Genomic DNA Goals Hepatobiliary Histology Human Immunocompetent Immunohistochemistry Individual Infrastructure International Joints Knock-out Knockout Mice Laboratories Liver Maintenance Malignant Neoplasms Malignant neoplasm of liver Mayo Clinic Cancer Center Medical History Medidata Molecular Analysis Molecular Genetics Neoplasms Online Systems Operative Surgical Procedures Outcome Paraffin Paraffin Embedding Pathologic Pathology Patient-Focused Outcomes Patients Pharmaceutical Preparations Phenotype Plasma Prevention strategy Process Program Research Project Grants Recording of previous events Registries Research Research Personnel Research Project Grants Resected Resource Sharing Resources Risk Factors Sampling Serum Services Site Sleeping Beauty Specimen Stains The Cancer Genome Atlas Tissue Embedding Tissue Microarray Tissues Toxin Transgenic Mice Transgenic Organisms Translational Research Tumor stage Universities Unresectable Vision anticancer research base biobank burden of illness cancer site career data acquisition demographics digital imaging disease registry early phase clinical trial genetic analysis hepatobiliary cancer improved liver cancer model liver transplantation mouse model patient derived xenograft model prevent programs prospective repository transplant registry treatment response tumor virtual

项目摘要

CORE C BIOSPECIMEN AND PATHOLOGY – PROJECT SUMMARY The Biospecimen and Pathology Core (Core C) will be responsible for accessioning and processing new biospecimens with annotated clinical data to provide the needed biospecimens for the four SPORE translational research projects, for the Developmental Research and Career Enhancement Programs, and for other investigators engaged in hepatobiliary cancer research. Core C will build on the existing International Hepatobiliary Neoplasia Registry and Biorepository, which has been coordinated by Dr. Lewis Roberts since 2001, and collaborate with additional existing biorepositories including the Genetics of Cholestatic Liver Diseases Registry, coordinated by Dr. Konstantinos Lazaridis, the Liver Transplant Registry coordinated by Dr. Kymberly Watt, and the Hepatobiliary Neoplasia Patient Derived Xenograft program which is jointly coordinated by Dr. Mark Truty and Dr. Roberts. Core C will also coordinate with The Fibrolamellar Hepatocellular Carcinoma Biorepository at the Rockefeller University under Dr. Sanford Simon, which will become part of the Core infrastructure. Core C will provide sample accessioning and pathology support for the early phase clinical trials as needed in the SPORE projects. Core C will coordinate with the Mayo Clinic Cancer Center Biospecimen Accessioning and Processing (BAP) Shared Resource to process blood samples to genomic DNA and serum and plasma aliquots, and with the Pathology Research Core (PRC) Shared Resource to provide histology and other tissue-based services, including paraffin and frozen sectioning, immunohistochemistry, tissue microarray (TMA) construction, and digital imaging. Requests for biospecimens will be reviewed by the Biospecimen Access Committee for Hepatobiliary Cancers (BAC-HEP), with priority access for SPORE investigators and consideration given primarily to scientific merit and availability of biospecimens. Input from the Biostatistics and Bioinformatics Core will be included in the evaluation of biospecimen requests. Dr. Torbenson will provide detailed annotation of the SPORE's tissue database for frozen and formalin-fixed paraffin-embedded tissues of all available patients who have had surgical resections for hepatobiliary cancer at Mayo Clinic, as well as for PDXs, a number of which are derived from percutaneous biopsies of patients with intermediate to advanced unresectable and metastatic disease. The availability of PDXs from biopsies of more advanced tumors will help to address the concern that most of the genetic and molecular analyses of liver and biliary tumors performed thus far, including for example, within The Cancer Genome Atlas project (TCGA), has been performed on early stage surgically resected tumors, not on the intermediate to advanced and metastatic stage tumors for which advances in therapy are urgently needed. Dr. Torbenson will also interpret IHC staining and provide other pathology support such as evaluating tumor samples from Sleeping Beauty, transgenic or knockout mouse models of liver and biliary cancer.

核心 C 生物样本和病理学 – 项目摘要生物样本和病理学核心（核心 C）将负责加入和处理新的样本带有注释临床数据的生物样本，为四个 SPORE 提供所需的生物样本转化研究项目，用于发展研究和职业提升计划，以及其他从事肝胆癌研究的研究人员将建立在现有的国际核心基础上。肝胆肿瘤登记和生物储存库，自此以来一直由 Lewis Roberts 博士负责协调 2001 年，并与其他现有生物样本库合作，包括胆汁淤积性肝脏遗传学疾病登记处由 Konstantinos Lazaridis 博士协调，肝脏移植登记处由 Dr. Konstantinos Lazaridis 协调。 Kymberly Watt 和肝胆肿瘤患者衍生异种移植项目由 Mark Truty 博士和 Roberts 博士协调，Core C 也将与 Fibrolamellar 协调。桑福德·西蒙 (Sanford Simon) 博士领导下的洛克菲勒大学肝细胞癌生物样本库，将成为核心基础设施的一部分 Core C 将为该项目提供样本加入和病理学支持。 SPORE Core C 项目需要的早期临床试验将与 Mayo Clinic Cancer 协调。生物样本登记和处理中心 (BAP) 共享资源，用于处理血液样本基因组 DNA 以及血清和血浆等份，并与病理学研究核心 (PRC) 共享提供组织学和其他基于组织的服务的资源，包括石蜡和冰冻切片，免疫组织化学、组织微阵列 (TMA) 构建和数字成像。生物样本申请将由肝胆癌生物样本获取委员会审查 (BAC-HEP)，SPORE 研究人员可优先使用，并主要考虑科学价值生物统计学和生物信息学核心的输入将包含在其中。 Torbenson 博士将提供 SPORE 组织的详细注释。所有可用患者的冷冻和福尔马林固定石蜡包埋组织的数据库 Mayo Clinic 的肝胆癌手术切除以及 PDX 手术，其中许多手术源自来自中度至晚期不可切除和转移性疾病患者的经皮活检。从更晚期肿瘤的活检中获得 PDX 将有助于解决大多数患者的担忧迄今为止对肝脏和胆道肿瘤进行的遗传和分子分析，包括例如癌症基因组图谱项目 (TCGA) 是针对早期手术切除的肿瘤进行的，而不是针对治疗亟待取得进展的中晚期和转移期肿瘤 Torbenson 博士还将解释 IHC 染色并提供其他病理学支持，例如评估。来自睡美人、肝癌和胆管癌转基因或基因敲除小鼠模型的肿瘤样本。